gulftoday8h
The bar for successful obesity drugs is rising
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
Knowridge6d
New drug can help prevent obesity, fatty liver disease
Liver disease affects millions of people in the United States, and one of its more serious forms, nonalcoholic fatty liver ...
BioPharma Dive8d
Novo’s next-gen obesity drug misses expectations in closely watched trial
Novo shares lost nearly a fifth of their value after an experimental combination treatment called cagrisema fell short of the ...
It’s time for a reality check about certain ‘weight loss’ drugs, and here’s why
Much hype surrounds drugs called GLP-1 agonists but they are intended for diabetes patients and people who are obese, not ...
Weight-loss drugs could help end obesity – but risks remain, WHO says
LONDON – A new class of weight-loss drugs developed by pharmaceutical companies Novo Nordisk and Eli Lilly “opens the ...
Medscape4d
Obesity Drug Zepbound Approved for Obstructive Sleep Apnea
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
Independent.ie7d
Novo Nordisk share price plunges as new obesity drug disappoints
Shares in Novo Nordisk fell yesterday, after it revealed disappointing results from a late-stage trial of its next-generation obesity drug CagriSema, wiping as much as $125bn (€120bn ...
Politico Europe9d
Weight-loss drugs can help ‘reverse’ obesity pandemic, say WHO experts
Blockbuster weight-loss drugs can help to stop and reverse the global obesity crisis, experts from the World Health ...
Novo Nordisk shares tumble as weight-loss drug trial data disappoints
Patients receiving Mounjaro, also called Zepbound in the US, lost an average of 22.5 per cent of their weight in phase three ...
Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...
Investing10d
Structure Therapeutics unveils new obesity drug candidate
The company’s research indicates that ACCG-2671 could offer a differentiated oral treatment option for obesity, with advantages including ... of ACCG-2671 using its GPCR structure-based drug discovery ...